血清NOX4 MUC1表达水平与Ⅲ期非小细胞肺癌患者放疗疗效及随访1年总生存率的关系研究  

Relationship between Expression Levels of Serum NOX4 and MUC1 with Radiotherapy Efficacy and 1-Year Overall Survival Rate in Patients with StageⅢNon-Small Cell Lung Cancer

作　　者：陆珏[1] 蔡梦娇[1] 张莹冰[1] LU Jue;CAI Mengjiao;ZHANG Yingbing(The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine,Shaanxi Xi'an 710061,China)

机构地区：[1]西安交通大学医学院第一附属医院肿瘤放射治疗科,陕西西安710061

出　　处：《河北医学》2024年第12期2028-2033,共6页Hebei Medicine

基　　金：陕西省自然科学基础研究计划项目,(编号:2019JM-553)。

摘　　要：目的:研究血清还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4(NOX4)、黏蛋白1(MUC1)表达水平与Ⅲ期非小细胞肺癌(NSCLC)患者放疗疗效及随访1年总生存率的关系。方法:选取2020年4月至2023年3月我院收治的102例Ⅲ期NSCLC患者,均进行放疗干预,并在放疗前检测血清NOX4、MUC1水平,另选择51例健康志愿者作为对照,比较两组血清NOX4、MUC1水平,以及放疗前不同临床特征的Ⅲ期NSCLC患者血清NOX4、MUC1水平。根据放疗效果将Ⅲ期NSCLC患者分为疗效良好组和疗效不佳组,对比两组血清NOX4、MUC1水平。所有患者均进行随访,以中位血清NOX4、MUC1水平为界,比较不同血清NOX4、MUC1水平的患者1年总生存率,并采用单因素和多因素Cox回归分析Ⅲ期NSCLC患者1年生存的影响因素。结果:NSCLC组血清NOX4、MUC1水平均高于对照组(P<0.05)。放疗前不同性别、年龄、体质指数(BMI)、肿瘤位置、肿瘤最大直径、病理分型的Ⅲ期NSCLC患者血清NOX4、MUC1水平比较差异均无统计学意义(P>0.05)。本次102例Ⅲ期NSCLC患者放疗结果显示,疗效良好组例数为55例,疗效不佳组例数为47例。疗效良好组血清NOX4、MUC1水平低于疗效不佳组(P<0.05)。高水平NOX4组患者1年总生存率低于低水平NOX4组(P<0.05),高水平MUC1组患者1年总生存率低于低水平MUC1组(P<0.05)。单因素和多因素Cox回归分析结果显示,血清NOX4、MUC1水平是Ⅲ期NSCLC患者放疗后1年生存的影响因素(P<0.05)。结论:Ⅲ期NSCLC患者血清NOX4、MUC1表达水平与其放疗疗效及随访1年总生存率有关,检测血清NOX4、MUC1水平有利于辅助评估患者放疗疗效和早期预后生存情况。Objective:To study the relationship between expression levels of serum nicotinamide adenine dinucleotide phosphate(NADPH)oxidase 4(NOX4)and mucin 1(MUC1)with radiotherapy efficacy and overall survival rate of 1-year follow-up in patients with stageⅢnon-small cell lung cancer(NSCLC).Methods:Totally 102 patients with stageⅢNSCLC in the hospital from April 2020 to March 2023 were selected for radiotherapy intervention,and serum NOX4 and MUC1 levels were detected before radiotherapy.Another 51 healthy volunteers were selected as controls.Before radiotherapy,the inter-group levels of serum NOX4 and MUC1 were compared,and the intra-class levels of serum NOX4 and MUC1 in patients stageⅢNSCLC with different clinical characteristics were assessed.According to the radiotherapy effect,patients with stageⅢNSCLC were divided into good efficacy group and poor efficacy group,and the levels of serum NOX4 and MUC1 were compared after radiotherapy.All patients were followed up,and the 1-year overall survival rates of different patients were compared using the median levels of serum NOX4 and MUC1.Univariate and multivariate Cox regression analyses were used to analyze the influencing factors of 1-year survival rate in patients with stageⅢNSCLC.Results:The levels of serum NOX4 and MUC1 in NSCLC group were significantly higher than those in control group(P<0.05).There were no statistical differences in serum NOX4 and MUC1 levels among stageⅢNSCLC patients with different genders,ages,body mass index(BMI)values,tumor locations,maximum tumor diameters and pathological types before radiotherapy(P>0.05).Among 102 patients with stageⅢNSCLC,the radiotherapy results showed that 55 patients were in the good efficacy group and 47 patients were in the poor efficacy group.Serum levels of NOX4 and MUC1 in good efficacy group were significantly lower than those in poor efficacy group(P<0.05).The 1-year overall survival rate in high-level NOX4 group was significantly lower than that in low-level NOX4 group(P<0.05),which in high-level

关 键 词：非小细胞肺癌 Ⅲ期 放疗 还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4 黏蛋白1 

分 类 号：R734.2[医药卫生—肿瘤]